Walter Offen

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

N. Bodick, Walter Offen, Allan I. Levey et al. · Archives of Neurology · 1997 · 685 citations

Medicine, Neurology, Pharmacology +17

Gatekeeping strategies for clinical trials that do not require all primary effects to be significant

Alexei Dmitrienko, Walter Offen, Peter H. Westfall · Statistics in Medicine · 2003 · 227 citations · Full text

Medicine, Biostatistics, Clinical Trial Regulation +10

Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America

Walter Offen, Christy Chuang‐Stein, Alex Dmitrienko et al. · Drug Information Journal · 2007 · 125 citations · Full text

Medicine, Biostatistics, Pharmacology +14

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

N. Bodick, Walter Offen, H E Shannon et al. · PubMed · 1997 · 116 citations

Medicine, Pharmacology, Pharmacotherapy +17

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist

Andrew Satlin, N. Bodick, Walter Offen et al. · American Journal of Psychiatry · 1997 · 76 citations

Medicine, Neurology, Pharmacology +17